Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 115

    1.

    Vorinostat in solid and hematologic malignancies.

    Siegel D, Hussein M, Belani C, Robert F, Galanis E, Richon VM, Garcia-Vargas J, Sanz-Rodriguez C, Rizvi S.

    J Hematol Oncol. 2009 Jul 27;2:31. Review.

    PMID:
    19635146
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    2.

    Evaluation of the long-term tolerability and clinical benefit of vorinostat in patients with advanced cutaneous T-cell lymphoma.

    Duvic M, Olsen EA, Breneman D, Pacheco TR, Parker S, Vonderheid EC, Abuav R, Ricker JL, Rizvi S, Chen C, Boileau K, Gunchenko A, Sanz-Rodriguez C, Geskin LJ.

    Clin Lymphoma Myeloma. 2009 Dec;9(6):412-6.

    PMID:
    19951879
    [PubMed - indexed for MEDLINE]
    3.

    FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma.

    Mann BS, Johnson JR, Cohen MH, Justice R, Pazdur R.

    Oncologist. 2007 Oct;12(10):1247-52.

    PMID:
    17962618
    [PubMed - indexed for MEDLINE]
    Free Article
    4.

    Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer.

    Blumenschein GR Jr, Kies MS, Papadimitrakopoulou VA, Lu C, Kumar AJ, Ricker JL, Chiao JH, Chen C, Frankel SR.

    Invest New Drugs. 2008 Feb;26(1):81-7. Epub 2007 Oct 25.

    PMID:
    17960324
    [PubMed - indexed for MEDLINE]
    5.

    Vorinostat in cutaneous T-cell lymphoma.

    Duvic M, Vu J.

    Drugs Today (Barc). 2007 Sep;43(9):585-99. Review.

    PMID:
    17940636
    [PubMed - indexed for MEDLINE]
    6.

    Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma.

    Crump M, Coiffier B, Jacobsen ED, Sun L, Ricker JL, Xie H, Frankel SR, Randolph SS, Cheson BD.

    Ann Oncol. 2008 May;19(5):964-9. Epub 2008 Feb 21.

    PMID:
    18296419
    [PubMed - indexed for MEDLINE]
    Free Article
    7.

    Vorinostat: A novel therapy for the treatment of cutaneous T-cell lymphoma.

    Kavanaugh SM, White LA, Kolesar JM.

    Am J Health Syst Pharm. 2010 May 15;67(10):793-7. Review. Erratum in: Am J Health Syst Pharm. 2010 Jul 15;67(14):1136. Kavanaugh, Shannon A [corrected to Kavanaugh, Shannon M].

    PMID:
    20479100
    [PubMed - indexed for MEDLINE]
    8.

    Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL).

    Duvic M, Talpur R, Ni X, Zhang C, Hazarika P, Kelly C, Chiao JH, Reilly JF, Ricker JL, Richon VM, Frankel SR.

    Blood. 2007 Jan 1;109(1):31-9. Epub 2006 Sep 7. Erratum in: Blood. 2007 Jun 15;109(12):5086.

    PMID:
    16960145
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    9.

    Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.

    Plosker GL, Figgitt DP.

    Drugs. 2003;63(8):803-43. Review.

    PMID:
    12662126
    [PubMed - indexed for MEDLINE]
    10.

    Early phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancer.

    Vansteenkiste J, Van Cutsem E, Dumez H, Chen C, Ricker JL, Randolph SS, Schöffski P.

    Invest New Drugs. 2008 Oct;26(5):483-8. Epub 2008 Apr 19.

    PMID:
    18425418
    [PubMed - indexed for MEDLINE]
    11.

    Phase I and pharmacokinetic study of vorinostat, a histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignancies.

    Ramalingam SS, Parise RA, Ramanathan RK, Lagattuta TF, Musguire LA, Stoller RG, Potter DM, Argiris AE, Zwiebel JA, Egorin MJ, Belani CP.

    Clin Cancer Res. 2007 Jun 15;13(12):3605-10. Epub 2007 May 17. Erratum in: Clin Cancer Res. 2007 Oct 15;13(20):6245. Ramananthan, Ramesh K [corrected to Ramanathan, Ramesh K].

    PMID:
    17510206
    [PubMed - indexed for MEDLINE]
    Free Article
    12.

    Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes.

    Garcia-Manero G, Yang H, Bueso-Ramos C, Ferrajoli A, Cortes J, Wierda WG, Faderl S, Koller C, Morris G, Rosner G, Loboda A, Fantin VR, Randolph SS, Hardwick JS, Reilly JF, Chen C, Ricker JL, Secrist JP, Richon VM, Frankel SR, Kantarjian HM.

    Blood. 2008 Feb 1;111(3):1060-6. Epub 2007 Oct 25.

    PMID:
    17962510
    [PubMed - indexed for MEDLINE]
    Free Article
    13.

    Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies.

    O'Connor OA, Heaney ML, Schwartz L, Richardson S, Willim R, MacGregor-Cortelli B, Curly T, Moskowitz C, Portlock C, Horwitz S, Zelenetz AD, Frankel S, Richon V, Marks P, Kelly WK.

    J Clin Oncol. 2006 Jan 1;24(1):166-73. Epub 2005 Dec 5.

    PMID:
    16330674
    [PubMed - indexed for MEDLINE]
    14.

    Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study.

    Galanis E, Jaeckle KA, Maurer MJ, Reid JM, Ames MM, Hardwick JS, Reilly JF, Loboda A, Nebozhyn M, Fantin VR, Richon VM, Scheithauer B, Giannini C, Flynn PJ, Moore DF Jr, Zwiebel J, Buckner JC.

    J Clin Oncol. 2009 Apr 20;27(12):2052-8. Epub 2009 Mar 23. Erratum in: J Clin Oncol. 2009 Jul 1;27(19):3262-3.

    PMID:
    19307505
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    15.

    Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma.

    Olsen EA, Kim YH, Kuzel TM, Pacheco TR, Foss FM, Parker S, Frankel SR, Chen C, Ricker JL, Arduino JM, Duvic M.

    J Clin Oncol. 2007 Jul 20;25(21):3109-15. Epub 2007 Jun 18.

    PMID:
    17577020
    [PubMed - indexed for MEDLINE]
    16.

    A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia.

    Gimsing P, Hansen M, Knudsen LM, Knoblauch P, Christensen IJ, Ooi CE, Buhl-Jensen P.

    Eur J Haematol. 2008 Sep;81(3):170-6. Epub 2008 May 27.

    PMID:
    18510700
    [PubMed - indexed for MEDLINE]
    17.

    Lack of therapeutic effect of the histone deacetylase inhibitor vorinostat in patients with metastatic radioiodine-refractory thyroid carcinoma.

    Woyach JA, Kloos RT, Ringel MD, Arbogast D, Collamore M, Zwiebel JA, Grever M, Villalona-Calero M, Shah MH.

    J Clin Endocrinol Metab. 2009 Jan;94(1):164-70. Epub 2008 Oct 14.

    PMID:
    18854394
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    19.

    Vorinostat, a histone deacetylase inhibitor, combined with pelvic palliative radiotherapy for gastrointestinal carcinoma: the Pelvic Radiation and Vorinostat (PRAVO) phase 1 study.

    Ree AH, Dueland S, Folkvord S, Hole KH, Seierstad T, Johansen M, Abrahamsen TW, Flatmark K.

    Lancet Oncol. 2010 May;11(5):459-64. Epub 2010 Apr 6.

    PMID:
    20378407
    [PubMed - indexed for MEDLINE]
    20.

    The role of histone deacetylase inhibitors in the treatment of patients with cutaneous T-cell lymphoma.

    Hymes KB.

    Clin Lymphoma Myeloma Leuk. 2010 Apr 1;10(2):98-109. Review.

    PMID:
    20371442
    [PubMed - indexed for MEDLINE]

      Display Settings:

      Format
      Items per page
      Sort by

      Send to:

      Choose Destination

      Supplemental Content

      Find related data

      Write to the Help Desk